早期阿司匹林使用与中度COVID-19患者院内死亡率的关联
该观察性队列研究纳入美国64个医疗系统2020年1月1日至2021年9月10日收治的112269例中度COVID-19住院患者,暴露为住院首日使用阿司匹林。经逆概率治疗加权后,阿司匹林组28天院内死亡率为10.2%,未用组为11.8%(OR 0.85;95%CI 0.79-0.92;P<.001);肺栓塞发生率亦较低(1.0% vs 1.4%;OR 0.71;95%CI 0.56-0.90;P=.004),深静脉血栓无显著差异。胃肠道出血、脑出血、输血及出血并发症复合终点在阿司匹林组未显著升高。作者认为需开展纳入中度COVID-19多样人群的随机临床试验以充分评估阿司匹林在高危患者中的疗效。
要点
- 中度COVID-19住院患者住院首日使用阿司匹林,28天院内死亡率10.2% vs 11.8%(OR 0.85;95%CI 0.79-0.92;P<.001)。
- 阿司匹林组肺栓塞发生率1.0% vs 1.4%(OR 0.71;95%CI 0.56-0.90;P=.004),深静脉血栓无显著差异。
- 胃肠道出血(0.8% vs 0.7%;OR 1.04;95%CI 0.82-1.33;P=.72)、脑出血(0.6% vs 0.4%;OR 1.32;95%CI 0.92-1.88;P=.13)、输血(2.7% vs 2.3%;OR 1.14;95%CI 0.99-1.32;P=.06)均未显著升高。
- 出血并发症复合终点3.7% vs 3.2%(OR 1.13;95%CI 1.00-1.28;P=.054),未显著升高。
- 年龄>60岁(61-80岁:OR 0.79;95%CI 0.72-0.87;P<.001;>80岁:OR 0.79;95%CI 0.69-0.91;P<.001)及合并症越多者似乎获益越大。
适用人群与场景
- 美国64个医疗系统2020年1月1日至2021年9月10日收治的中度COVID-19住院成人患者,共112269例纳入分析。
- 全队列中位年龄63岁(IQR 47-74岁);16.1%为非裔美国人,3.8%为亚裔,52.7%为白人,5.0%为其他种族和族裔,22.4%种族和族裔未知。
处置流程与药物剂量
- 暴露定义为住院首日使用阿司匹林;原文未给出阿司匹林剂量、给药途径与疗程。
研究设计与关键结果
- 观察性队列研究,筛查2446650例COVID-19阳性患者,189287例住院,112269例符合研究纳入标准;来自美国64个医疗系统。
- 主要终点28天院内死亡:全队列院内死亡发生率10.9%;经逆概率治疗加权后阿司匹林组10.2% vs 未用组11.8%(OR 0.85;95%CI 0.79-0.92;P<.001)。
- 次要终点肺栓塞:阿司匹林组1.0% vs 未用组1.4%(OR 0.71;95%CI 0.56-0.90;P=.004);深静脉血栓无显著差异。
- 安全性:胃肠道出血0.8% vs 0.7%(OR 1.04;95%CI 0.82-1.33;P=.72);脑出血0.6% vs 0.4%(OR 1.32;95%CI 0.92-1.88;P=.13);输血2.7% vs 2.3%(OR 1.14;95%CI 0.99-1.32;P=.06);出血并发症复合终点3.7% vs 3.2%(OR 1.13;95%CI 1.00-1.28;P=.054)。
- 亚组:年龄61-80岁OR 0.79(95%CI 0.72-0.87;P<.001),>80岁OR 0.79(95%CI 0.69-0.91;P<.001)。
- 亚组:1种合并症死亡率6.4% vs 9.2%(OR 0.68;95%CI 0.55-0.83;P<.001);2种合并症10.5% vs 12.8%(OR 0.80;95%CI 0.69-0.93;P=.003);3种合并症13.8% vs 17.0%(OR 0.78;95%CI 0.68-0.89;P<.001);>3种合并症17.0% vs 21.6%(OR 0.74;95%CI 0.66-0.84;P<.001)。
证据类型、等级与局限
- 证据类型:观察性队列研究;采用边际结构Cox和logistic回归模型计算院内死亡比值比,并用逆概率治疗加权减少混杂偏倚、平衡组间特征。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,需开展纳入中度COVID-19多样人群的随机临床试验,以充分评估阿司匹林在高危患者中的疗效。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Prior observational studies suggest that aspirin use may be associated with reduced mortality in high-risk hospitalized patients with COVID-19, but aspirin's efficacy in patients with moderate COVID-19 is not well studied.
OBJECTIVE: To assess whether early aspirin use is associated with lower odds of in-hospital mortality in patients with moderate COVID-19.
DESIGN, SETTING, AND PARTICIPANTS: Observational cohort study of 112 269 hospitalized patients with moderate COVID-19, enrolled from January 1, 2020, through September 10, 2021, at 64 health systems in the United States participating in the National Institute of Health's National COVID Cohort Collaborative (N3C).
EXPOSURE: Aspirin use within the first day of hospitalization.
MAIN OUTCOME AND MEASURES: The primary outcome was 28-day in-hospital mortality, and secondary outcomes were pulmonary embolism and deep vein thrombosis. Odds of in-hospital mortality were calculated using marginal structural Cox and logistic regression models. Inverse probability of treatment weighting was used to reduce bias from confounding and balance characteristics between groups.
RESULTS: Among the 2 446 650 COVID-19-positive patients who were screened, 189 287 were hospitalized and 112 269 met study inclusion. For the full cohort, Median age was 63 years (IQR, 47-74 years); 16.1% of patients were African American, 3.8% were Asian, 52.7% were White, 5.0% were of other races and ethnicities, 22.4% were of unknown race and ethnicity. In-hospital mortality occurred in 10.9% of patients. After inverse probability treatment weighting, 28-day in-hospital mortality was significantly lower in those who received aspirin (10.2% vs 11.8%; odds ratio [OR], 0.85; 95% CI, 0.79-0.92; P < .001). The rate of pulmonary embolism, but not deep vein thrombosis, was also significantly lower in patients who received aspirin (1.0% vs 1.4%; OR, 0.71; 95% CI, 0.56-0.90; P = .004). Patients who received early aspirin did not have higher rates of gastrointestinal hemorrhage (0.8% aspirin vs 0.7% no aspirin; OR, 1.04; 95% CI, 0.82-1.33; P = .72), cerebral hemorrhage (0.6% aspirin vs 0.4% no aspirin; OR, 1.32; 95% CI, 0.92-1.88; P = .13), or blood transfusion (2.7% aspirin vs 2.3% no aspirin; OR, 1.14; 95% CI, 0.99-1.32; P = .06). The composite of hemorrhagic complications did not occur more often in those receiving aspirin (3.7% aspirin vs 3.2% no aspirin; OR, 1.13; 95% CI, 1.00-1.28; P = .054). Subgroups who appeared to benefit the most included patients older than 60 years (61-80 years: OR, 0.79; 95% CI, 0.72-0.87; P < .001; >80 years: OR, 0.79; 95% CI, 0.69-0.91; P < .001) and patients with comorbidities (1 comorbidity: 6.4% vs 9.2%; OR, 0.68; 95% CI, 0.55-0.83; P < .001; 2 comorbidities: 10.5% vs 12.8%; OR, 0.80; 95% CI, 0.69-0.93; P = .003; 3 comorbidities: 13.8% vs 17.0%, OR, 0.78; 95% CI, 0.68-0.89; P < .001; >3 comorbidities: 17.0% vs 21.6%; OR, 0.74; 95% CI, 0.66-0.84; P < .001).
CONCLUSIONS AND RELEVANCE: In this cohort study of US adults hospitalized with moderate COVID-19, early aspirin use was associated with lower odds of 28-day in-hospital mortality. A randomized clinical trial that includes diverse patients with moderate COVID-19 is warranted to adequately evaluate aspirin's efficacy in patients with high-risk conditions.
参考来源
- Chow JH, Rahnavard A, Gomberg-Maitland M, et al. Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19. JAMA Netw Open. 2022. PMID: 35323950. doi:10.1001/jamanetworkopen.2022.3890
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。